These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 18930407)

  • 1. Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.
    Chakrapani H; Kalathur RC; Maciag AE; Citro ML; Ji X; Keefer LK; Saavedra JE
    Bioorg Med Chem; 2008 Nov; 16(22):9764-71. PubMed ID: 18930407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide donor of the diazeniumdiolate class with potent antineoplastic activity.
    Shami PJ; Saavedra JE; Wang LY; Bonifant CL; Diwan BA; Singh SV; Gu Y; Fox SD; Buzard GS; Citro ML; Waterhouse DJ; Davies KM; Ji X; Keefer LK
    Mol Cancer Ther; 2003 Apr; 2(4):409-17. PubMed ID: 12700285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitric oxide-releasing prodrug triggers cancer cell death through deregulation of cellular redox balance.
    Maciag AE; Holland RJ; Robert Cheng YS; Rodriguez LG; Saavedra JE; Anderson LM; Keefer LK
    Redox Biol; 2013; 1(1):115-24. PubMed ID: 24024144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.
    Nandurdikar RS; Maciag AE; Citro ML; Shami PJ; Keefer LK; Saavedra JE; Chakrapani H
    Bioorg Med Chem Lett; 2009 May; 19(10):2760-2. PubMed ID: 19364650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and in vitro anti-leukemic activity of structural analogues of JS-K, an anti-cancer lead compound.
    Chakrapani H; Goodblatt MM; Udupi V; Malaviya S; Shami PJ; Keefer LK; Saavedra JE
    Bioorg Med Chem Lett; 2008 Feb; 18(3):950-3. PubMed ID: 18178089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
    Maciag AE; Saavedra JE; Chakrapani H
    Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the c-Jun N-terminal kinase/activating transcription factor 3 (ATF3) pathway characterizes effective arylated diazeniumdiolate-based nitric oxide-releasing anticancer prodrugs.
    Maciag AE; Nandurdikar RS; Hong SY; Chakrapani H; Diwan B; Morris NL; Shami PJ; Shiao YH; Anderson LM; Keefer LK; Saavedra JE
    J Med Chem; 2011 Nov; 54(22):7751-8. PubMed ID: 22003962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K.
    Sjödin B; Mannervik B
    Sci Rep; 2021 Oct; 11(1):20765. PubMed ID: 34675290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
    Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
    J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular distribution studies of the nitric oxide-generating antineoplastic prodrug O(2) -(2,4-dinitrophenyl)1-((4-ethoxycarbonyl)piperazin-1-yl)diazen-1-ium-1,2-diolate formulated in Pluronic P123 micelles.
    Kaur I; Terrazas M; Kosak KM; Kern SE; Boucher KM; Shami PJ
    J Pharm Pharmacol; 2013 Sep; 65(9):1329-36. PubMed ID: 23927471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells.
    Simeone AM; McMurtry V; Nieves-Alicea R; Saavedra JE; Keefer LK; Johnson MM; Tari AM
    Breast Cancer Res; 2008; 10(3):R44. PubMed ID: 18474097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JS-K, a glutathione/glutathione S-transferase-activated nitric oxide releasing prodrug inhibits androgen receptor and WNT-signaling in prostate cancer cells.
    Laschak M; Spindler KD; Schrader AJ; Hessenauer A; Streicher W; Schrader M; Cronauer MV
    BMC Cancer; 2012 Mar; 12():130. PubMed ID: 22462810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingosine 1-Phosphate Liposomes for Targeted Nitric Oxide Delivery to Mediate Anticancer Effects against Brain Glioma Tumors.
    Liu Y; Wang X; Li J; Tang J; Li B; Zhang Y; Gu N; Yang F
    Adv Mater; 2021 Jul; 33(30):e2101701. PubMed ID: 34106489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.
    Nandurdikar RS; Maciag AE; Holland RJ; Cao Z; Shami PJ; Anderson LM; Keefer LK; Saavedra JE
    Bioorg Med Chem; 2012 May; 20(9):3094-9. PubMed ID: 22480849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of JS-K, a novel anti-cancer nitric oxide prodrug, on gene expression in human hepatoma Hep3B cells.
    Dong R; Wang X; Wang H; Liu Z; Liu J; Saavedra JE
    Biomed Pharmacother; 2017 Apr; 88():367-373. PubMed ID: 28122301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.
    Liu J; Li C; Qu W; Leslie E; Bonifant CL; Buzard GS; Saavedra JE; Keefer LK; Waalkes MP
    Mol Cancer Ther; 2004 Jun; 3(6):709-14. PubMed ID: 15210857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nitric oxide prodrug JS-K is effective against non-small-cell lung cancer cells in vitro and in vivo: involvement of reactive oxygen species.
    Maciag AE; Chakrapani H; Saavedra JE; Morris NL; Holland RJ; Kosak KM; Shami PJ; Anderson LM; Keefer LK
    J Pharmacol Exp Ther; 2011 Feb; 336(2):313-20. PubMed ID: 20962031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound.
    Chakrapani H; Wilde TC; Citro ML; Goodblatt MM; Keefer LK; Saavedra JE
    Bioorg Med Chem; 2008 Mar; 16(5):2657-64. PubMed ID: 18060792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.
    Shami PJ; Saavedra JE; Bonifant CL; Chu J; Udupi V; Malaviya S; Carr BI; Kar S; Wang M; Jia L; Ji X; Keefer LK
    J Med Chem; 2006 Jul; 49(14):4356-66. PubMed ID: 16821795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of a Pluronic(®) P123 formulation on the nitric oxide-generating drug JS-K.
    Kaur I; Kosak KM; Terrazas M; Herron JN; Kern SE; Boucher KM; Shami PJ
    Pharm Res; 2015 Apr; 32(4):1395-406. PubMed ID: 25330743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.